AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

Core Insights - AbbVie has entered into a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services, which will enhance AbbVie's drug delivery device manufacturing capabilities and capacity [1][3] Group 1: Acquisition Details - The acquisition includes the manufacturing site and associated intellectual property, with an investment of over $175 million for modernization and integration into AbbVie's global manufacturing network [2][3] - The transaction is expected to close in mid-2026, pending closing conditions [4][7] Group 2: Employment and Economic Impact - AbbVie plans to hire approximately 200 employees at the new site, significantly expanding its presence and economic impact in Arizona [2][4] - AbbVie currently employs around 29,000 people in the U.S., with over 6,000 at its 11 manufacturing sites [4] Group 3: Long-term Investment Strategy - Over the next decade, AbbVie is committing more than $10 billion in capital to support innovation and expand manufacturing capabilities in the U.S. [3][7] - This acquisition aligns with AbbVie's strategy to enhance production for current and next-generation immunology and neuroscience medicines [3][7]